New treatments for chronic myelomonocytic leukemia
Novel targeted therapies for chronic myelomonocytic leukemia
['FUNDING_CAREER'] · DANA-FARBER CANCER INST · NIH-10911848
This study is looking at chronic myelomonocytic leukemia (CMML) to see how changes in a specific gene affect the disease and how a drug called dasatinib might help treat it, while also figuring out why some patients might not respond to the treatment and what other options could work better together with it.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10911848 on ClinicalTrials.gov |
What this research studies
This research focuses on chronic myelomonocytic leukemia (CMML), a serious blood cancer with limited treatment options. It investigates the role of the CBL gene and its mutations in driving the disease, particularly how the LYN kinase contributes to cancer cell growth. The study aims to explore the effectiveness of dasatinib, a drug that inhibits LYN, and to understand how resistance to this treatment develops. Additionally, it seeks to identify other potential therapies that could be combined with dasatinib to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with chronic myelomonocytic leukemia who have mutations in the CBL gene.
Not a fit: Patients with CMML who do not have CBL mutations may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with CBL-mutant CMML.
How similar studies have performed: Previous research has shown promising results with targeted therapies in similar hematologic malignancies, suggesting potential for success in this approach.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BELIZAIRE, ROGER VINCENT — DANA-FARBER CANCER INST
- Study coordinator: BELIZAIRE, ROGER VINCENT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.